Companies
Novartis
PharmaceuticalsBasel, SwitzerlandNVS75,267 employees
More about Novartis
Drugmaker that develops and sells prescription medicines for heart, kidney, immune, neurological diseases and cancer
Revenue
$54.5B
Fiscal 2025 net sales, up 8.4%
Employees
75,267
As of December 2025, full-time equivalents
Stock
NVS
New York Stock Exchange
Headquarters
Basel, Switzerland
CEO
Vas Narasimhan
Since 2018
BrandsEntresto, Kisqali, Cosentyx, Kesimpta, Leqvio, Pluvicto
Current strategyOperating as a pure-play innovative medicines company focused on cardiovascular-renal-metabolic, immunology, neuroscience and oncology
Recent workforce changesMore than 170 New Jersey roles cut in March and April 2026, plus 60 at Tourmaline Bio in May 2026
CompetitorsRoche, AstraZeneca, Pfizer
Related companiesRocheAstraZenecaSanofi
Checked October 11, 2026 · Sources: sec.gov, prod1.novartis.com, guidechem.com
Be the first to post about Novartis
No one has started a discussion here yet. Yours is anonymous and appears right away, and we don’t store who wrote it.
Or follow Novartis to see the first post in your watchlist.
Follow Novartis in a feed reader, no account needed: RSS feed